基于循证支持的用药指导在贝伐珠单抗治疗结直肠癌患者中的应用

Application of Evidence-Based Medication Guidance in the Treatment of Colorectal Cancer Patients with Bevacizumab

摘要: 目的：探讨基于循证支持的用药指导在贝伐珠单抗治疗CRC患者中的应用效果。方法：选取2022年8月至2024年8月本院收治的90例贝伐珠单抗治疗CRC患者，以随机数字表法分为对照组(n = 45)与干预组(n = 45)，对照组采用常规用药指导，干预组采用基于循证支持的用药指导，比较两组焦虑抑郁情绪、治疗依从性、用药指导满意度。结果：两组干预后焦虑自评量表(SAS)、抑郁自评量表(SDS)评分下降(P < 0.05)，干预组较对照组更低(P < 0.05)；干预组治疗依从性、用药指导满意度较对照组更高(P < 0.05)。结论：基于循证支持的用药指导方案在贝伐珠单抗治疗CRC患者中，能够改善焦虑、抑郁情绪，提高其治疗依从性、用药指导满意度。

Abstract: Objective: To explore the application effect of evidence-based medication guidance in the treatment of colorectal cancer (CRC) patients with bevacizumab. Methods: A total of 90 patients with CRC treated with bevacizumab from August 2022 to August 2024 who were admitted to our hospital were selected and were divided into the control group (n = 45, medication guidance) and the intervention group (n = 45, evidence-based medication guidance) using a random number table. The anxiety and depression, treatment compliance, and medication guidance satisfaction were compared in both groups. Results: After intervention, the Self Rating Anxiety Scale (SAS) and Self Rating Depression Scale (SDS) scores were decreased in both groups (P < 0.05), and in comparison with the control group, the intervention group was lower (P < 0.05). In comparison with the control group, treatment compliance and medication guidance satisfaction of the intervention group were higher (P < 0.05). Conclusion: Evidence-based medication guidance protocols can improve anxiety and depression, enhance treatment compliance, and improve medication guidance satisfaction in CRC patients treated with bevacizumab.